Subscribe to RSS
DOI: 10.1055/a-1891-6864
LncRNA MAGI2-AS3 Inhibits Prostate Cancer Progression by Targeting the miR-142-3p
![](https://www.thieme-connect.de/media/hmr/202211/lookinside/thumbnails/2022-05-0150_10-1055-a-1891-6864-1.jpg)
Abstract
Prostate cancer is a common male cancer with high morbidity and mortality worldwide. According to current research, the integration of long non-coding RNA (lncRNAs) and microRNA(miRNAs) can be expressed in a variety of cancers and play an important role in diagnosis. Based on this, this study explored the clinical role of lncRNA MAGI2-AS3 (MAGI2-AS3) in prostate cancer. By detecting the expression levels of MAGI2-AS3 and miR-142-3p, the correlation between the MAGI2-AS3 expression and the characteristics of clinical data was analyzed. ROC curve analysis was performed and the area under the ROC curve (AUC) was used to evaluate the diagnostic value of MAGI2-AS3 in distinguishing prostate cancer patients from healthy controls. The function of MAGI2-AS3 in prostate cancer cells was explored through CCK-8 and Transwell assays, and the relationship between MAGI2-AS3 and miR-142-3p was investigated by luciferase activity assay. MAGI2-AS3 has descended expression while miR-142-3p has an ascendant one in prostate cancer serum samples and cells. ROC curve analysis revealed that the AUC was 0.953 for MAGI2-AS3, with a sensitivity of 91.5% and specificity of 84.7%. Overexpression of MAGI2-AS3 in LNCaP and PC3 cells suppressed the biological function of the cell including proliferation capacity, migration level, and invasion. MAGI2-AS3 was considered a diagnostic biomarker for prostate cancer patients and inhibited prostate cancer progression by targeting miR-142-3p.
Publication History
Received: 18 May 2022
Accepted after revision: 22 June 2022
Article published online:
09 August 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Chen L, Hu W, Li G. et al. Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13. Cell Mol Biol Lett 2019; 24: 20
- 2 Kong Z, Wan X, Lu Y. et al. Circular RNA circFOXO3 promotes prostate cancer progression through sponging miR-29a-3p. J Cell Mol Med 2020; 24: 799-813
- 3 Wang D, Lu G, Shao Y. et al. MiR-182 promotes prostate cancer progression through activating Wnt/β-catenin signal pathway. Biomed Pharmacother 2018; 99: 334-339
- 4 Wang Y, Zhang Q, Guo B. et al. miR-1231 is downregulated in prostate cancer with prognostic and functional implications. Oncol Res Treat 2020; 43: 78-86
- 5 Lughezzani G, Sun M, Budäus L. et al. Effect of the number of biopsy cores on prostate cancer detection and staging. Fut Oncol (London, England) 2010; 6: 381-390
- 6 Chen Y, Li Z, Chen X. et al. Long non-coding RNAs: from disease code to drug role. Acta Pharm Sinica B 2021; 11: 340-354
- 7 Matsushita D, Arigami T, Okubo K. et al. The diagnostic and prognostic value of a liquid biopsy for esophageal cancer: a systematic review and meta-analysis. Cancers 2020; 12: 3070
- 8 Xu M, Yan Y, Zhu M. et al. Effects of long non-coding RNA Gm14461 on pain transmission in trigeminal neuralgia. J Inflam (London, England) 2020; 17: 1
- 9 Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol 2013; 45: 1895-1910
- 10 Lam MT, Li W, Rosenfeld MG. et al. Enhancer RNAs and regulated transcriptional programs. Trends Biochem Sci 2014; 39: 170-182
- 11 Fang Y, Fullwood MJ. Roles, Functions, and mechanisms of long non-coding RNAs in cancer. Genom Poteom Bioinform 2016; 14: 42-54
- 12 Zhou Z, Liu H, Wang C. et al. Long non-coding RNAs as novel expression signatures modulate DNA damage and repair in cadmium toxicology. Sci Rep 2015; 5: 15293
- 13 Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. Eur Rev Med Pharmacol Sci 2017; 21: 3850-3856
- 14 Cao HL, Liu ZJ, Huang PL. et al. lncRNA-RMRP promotes proliferation, migration and invasion of bladder cancer via miR-206. Eur Rev Med Pharmacol Sci 2019; 23: 1012-1021
- 15 Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res 2017; 77: 3965-3981
- 16 Cai J, Chen Z, Chen X. et al. Coexpression network analysis identifies a novel nine-RNA signature to improve prognostic prediction for prostate cancer patients. BioMed Res Int 2020; 4264291
- 17 Li D, Wang J, Zhang M. et al. LncRNA MAGI2-AS3 is regulated by BRD4 and promotes gastric cancer progression via maintaining ZEB1 overexpression by sponging miR-141/200a. Mol Ther Nucleic Acids 2020; 19: 109-123
- 18 Tang C, Cai Y, Jiang H. et al. LncRNA MAGI2-AS3 inhibits bladder cancer progression by targeting the miR-31-5p/TNS1 axis. Aging 2020; 12: 25547-25563
- 19 [Anonymous] Prostate cancer. Nursing Stand [Royal College of Nursing (Great Britain): 1987] 2016; 30: 17
- 20 Xing C, Sun SG, Yue ZQ. et al. Role of lncRNA LUCAT1 in cancer. Biomed Pharmacother 2021; 134: 111158
- 21 Iyer MK, Niknafs YS, Malik R. et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 2015; 47: 199-208
- 22 Su W, Guo C, Wang L. et al. LncRNA MIR22HG abrogation inhibits proliferation and induces apoptosis in esophageal adenocarcinoma cells via activation of the STAT3/c-Myc/FAK signaling. Aging 2019; 11: 4587-4596
- 23 Sui Y, Chi W, Feng L. et al. LncRNA MAGI2-AS3 is downregulated in non-small cell lung cancer and may be a sponge of miR-25. BMC Pulm Med 2020; 20: 59
- 24 Kai-Xin L, Cheng C, Rui L. et al. Roles of lncRNA MAGI2-AS3 in human cancers. Biomed Pharmacother 2021; 141: 111812
- 25 Chang H, Zhang X, Li B. et al. MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation and migration in ovarian cancer through targeting miR-525-5p/MXD1 axis. Cancer Med 2020; 9: 6377-6386
- 26 Du S, Hu W, Zhao Y. et al. Long non-coding RNA MAGI2-AS3 inhibits breast cancer cell migration and invasion via sponging microRNA-374a. Cancer Biomark Sect A 2019; 24: 269-277
- 27 Xu T, He BS, Pan B. et al. MiR-142-3p functions as a tumor suppressor by targeting RAC1/PAK1 pathway in breast cancer. J Cell Physiol 2020; 235: 4928-4940
- 28 Tan YF, Chen ZY, Wang L. et al. MiR-142-3p functions as an oncogene in prostate cancer by targeting FOXO1. J Cancer 2020; 11: 1614-1624
- 29 Ren J, Li W, Pan G. et al. miR-142-3p modulates cell invasion and migration via PKM2-mediated aerobic glycolysis in colorectal cancer. Anal Cell Pathol (Amsterdam) 2021; 9927720
- 30 Peng L, Sang H, Wei S. et al. circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p/ROCK2. Mol Cancer 2020; 19: 156
- 31 Hua YQ, Zhu YD, Xie GQ. et al. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upregulating TWF1. Aging 2019; 11: 8860-8878